Tango Therapeutics Enters and Terminates Agreements

TL;DR

Tango Therapeutics made and broke a deal on Nov 18th.

AI Summary

Tango Therapeutics, Inc. entered into a material definitive agreement on November 18, 2025. The company also terminated a material definitive agreement on the same date. Further details regarding these agreements are not provided in this excerpt.

Why It Matters

The entry into and termination of material definitive agreements can significantly impact a company's strategic direction, partnerships, and financial obligations.

Risk Assessment

Risk Level: medium — The nature of the agreements (entry and termination) suggests potential shifts in business strategy or partnerships, which carries inherent risk.

Key Players & Entities

• Tango Therapeutics, Inc. (company) — Registrant
• November 18, 2025 (date) — Date of earliest event reported
• BCTG Acquisition Corp. (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — ich registered Common stock, par value $0.001 per share TNGX The Nasdaq Global Ma
• $100,000,000 — Company may sell up to an aggregate of $100,000,000 of shares of its common stock. Any Sh

Filing Documents

• d921087d8k.htm (8-K) — 27KB
• 0001193125-25-290679.txt ( ) — 139KB
• tngx-20251118.xsd (EX-101.SCH) — 3KB
• tngx-20251118_lab.xml (EX-101.LAB) — 18KB
• tngx-20251118_pre.xml (EX-101.PRE) — 11KB
• d921087d8k_htm.xml (XML) — 4KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 18, 2025 TANGO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39485 85-1195036 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 201 Brookline Ave. , Suite 901 Boston , MA 02215 (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code: 857 - 320-4900 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b)under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c)under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.001 per share TNGX The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item1.01 Entry into a Material Definitive Agreement. On November 21, 2025, Tango Therapeutics, Inc. (the "Company") entered into a Sales Agreement (the "Sales Agreement") with Leerink Partners LLC (the "Agent"), pursuant to which the Company may sell, from time to time, at its option, shares of the Company's common stock, $0.001 par value per share (the "Shares"), through the Agent, as sales agent (the "ATM Offering"). Pursuant to the prospectus supplement (the "ATM Prospectus Supplement") filed with the Securities and Exchange Commission (the "SEC") on November 21, 2025, the Company may sell up to an aggregate of $100,000,000 of shares of its common stock. Any Shares to be offered and sold under the Sales Agreement will be issued and sold by methods deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or in negotiated transactions, if authorized by the Company. On November 21, 2025, the Company filed the ATM Prospectus Supplement with the SEC in connection with the offer and sale of the Shares pursuant to the Sales Agreement. The legal opinion of Goodwin Procter LLP relating to the legality of the issuance and sale of the Shares pursuant to the ATM Offering is attached as Exhibit 5.2 to the Registration Statement and is incorporated by reference herein. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Shares nor shall there be any sale of the Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The foregoing description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Sales Agreement, which is attached as Exhibit 1.2 to the Registration Statement and is incorporated by reference herein. Item1.02 Termination of a Material Definitive Agreement. As previously disclosed, on September 1, 2022, the Company entered into an Open Market Sales Agreement SM (the "Jefferies Sales Agreement") with Jefferies LLC ("Jefferies"), as sales agent, to sell, at its option, shares of the Company's common stock, $0.001 par value per share, from time to time, through Jefferies, as the Company's sales agent (the "2022 ATM Program"). Pursuant to the Registration Statement on Form S-3 (File No. 333-267224) filed with the SEC on September 1, 2022, which was declared effective on September 12, 2022 (the "2022 Registration Statement"), and a prospectus supplement included therein, and to the Registration Statement on Form S-3 (File No. 333-287202), filed with the SEC on May 12, 2025, which was declared effective on May 21, 2025, and a prospectus supplement included therein, the Company could sell up to an aggregate of $100,000,000 of shares of its common stock (the "Jefferies ATM Shares"). On November 18, 2025, the Company

View Full Filing

View this 8-K filing on SEC EDGAR